Small bowel resection rates in Crohnʼs disease and the indication for surgery over time: Experience from a large tertiary care center
- 1 May 2010
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 16 (5), 830-835
- https://doi.org/10.1002/ibd.21118
Abstract
Our primary aim was to determine if the rate of small bowel resection (SBR) has declined over time among Crohn's disease (CD) patients seen at a single academic institution. A secondary aim was to establish whether the indication for surgery has changed. Patients with a primary or secondary ICD-9 code for CD (555.0-555.9) who underwent SBR at the University of Pittsburgh were included. Patients were divided into 4 separate time periods based on when they had surgery: 1995-1998 (Period 1), 1999-2001 (Period 2), 2002-2004 (Period 3), and 2005-2007 (Period 4). Medical records were reviewed for the 6 months preceding surgery. Use of 5-ASAs, immunomodulators (IMs), tumor necrosis factor (TNF) antagonists, and corticosteroids were noted. Disease behavior was defined as nonstricturing, nonpenetrating (B1), stricturing (B2), and penetrating (B3). Proportions of patients undergoing SBR were calculated according to calendar cohort and these rates were examined for time trends. In all, 227 unique patients were analyzed for a total of 236 surgeries. The rates of 5-ASA, IM, and corticosteroid use were similar across the 4 time periods. By contrast, TNF antagonist usage progressively increased over time (0%, 18%, 34%, 35%; P = 0.0002). The annual rate of SBR per period did not change (1.6%, 1.9%, 1.6%, 1.9%; P = 0.93). Similarly, the disease behavior did not change over time. While the frequency of TNF antagonist use in CD at the University of Pittsburgh has increased over time, the rate of SBR and indication for surgery has remained unchanged. These findings may be explained by long-standing, complicated disease refractory to medical therapy.Keywords
This publication has 18 references indexed in Scilit:
- Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohortGut, 2008
- Natural History of Pediatric Crohn's Disease: A Population-Based Cohort StudyGastroenterology, 2008
- Therapy of Metronidazole With Azathioprine to Prevent Postoperative Recurrence of Crohn's Disease: A Controlled Randomized TrialGastroenterology, 2008
- T1192 Relationship Between Inflammatory Bowel Disease and Perinatal FactorsGastroenterology, 2008
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- The Montreal classification of inflammatory bowel disease: controversies, consensus, and implicationsGut, 2006
- Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgeryGut, 2005
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Risk Factors for Surgery and Postoperative Recurrence in Crohn’s DiseaseAnnals of Surgery, 2000
- Primary and Recurrent Crohnʼs DiseaseAnnals of Surgery, 1991